Oncodesign Precision Medicine S.A.: insider trades · France · AMF

About Oncodesign Precision Medicine S.A.

Oncodesign Precision Medicine S.A. (OPM), listed under ISIN FR001400CM63 and ticker ALOPM, is a French biopharmaceutical company focused on precision medicine, with a core strategic emphasis on resistant and metastatic cancers as well as selected neurodegenerative disorders. The company was created following the spin-off announced by Oncodesign in July 2022, which transferred the Biotech business, including artificial intelligence capabilities, to OPM. Operational activity began in 2022, building on the scientific legacy of the Oncodesign group, founded in 1995 in Dijon. The company remains anchored in Dijon, in the Bourgogne-Franche-Comté region of France, a long-standing hub for life sciences and drug discovery. OPM’s business model is built around a proprietary technology stack that differentiates it within the European biotech landscape. Its key platforms include Nanocyclix®, a chemistry engine designed to generate novel small-molecule kinase inhibitors; OncoSNIPER, an artificial-intelligence-based target identification platform; and a theranostics/radiotheranostics activity focused on vectorized systemic radiotherapy approaches. Together, these capabilities allow OPM to cover a broad part of the drug-development chain, from target selection and candidate design through preclinical and clinical development. The company’s pipeline includes flagship programs such as OPM-101, a RIPK2 inhibitor being developed in oncology, OPM-201, a LRRK2 inhibitor originally associated with Parkinson’s disease, and OPM-102, another oncology-oriented kinase program in preclinical development. OPM has also established scientific and industrial collaborations, notably with Servier, which exercised an option to license the LRRK2 program, and with other research partners. These partnerships are strategically important because they can generate milestone payments, licensing revenue and external funding, which are essential sources of value creation for a development-stage biotech. In market terms, OPM remains a small-cap, clinical-stage company with the typical profile of an innovation-driven biotech: high R&D intensity, limited operating visibility relative to mature pharmaceutical groups, and a funding model that may rely on capital increases, grants and partnership income. That said, the upside potential can be significant if clinical data are positive and programs advance toward regulatory milestones. OPM regularly communicates on its clinical and financial progress, underscoring its focus on advancing proprietary assets to more advanced development stages. Overall, the company positions itself as a French specialist in precision medicine at the intersection of oncology, neuro-inflammation and AI-enabled drug discovery.